Back

Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials

30 August 2026 (17:30 - 17:40)
Organised by: Logo
Congress Presentation Part of: Drivers of heart failure with preserved ejection fraction Heart Failure with Preserved Ejection Fraction (HFpEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Henri Lu

Lausanne University Hospital, Lausanne (Switzerland)

5 More presentations in this session

Presentation thumbnail
Unmasking the supernormal: intrinsic cardiomyopathy drives poor outcomes in heart failure with supranormal ejection fraction
Doctor Y. Chen (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Time-series analysis of the chronotropic response and its association with HFpEF risk scoring and adverse events
Doctor M. Vermeiren (Leuven, BE) Professor P. Sinnaeve (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Association between LDL-C levels and outcomes in patients with heart failure with preserved ejection fraction: a real-world study
Doctor S. Jiang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
FKBP11 drives cardiomyocyte ferroptosis in HFpEF by destabilizing GPX4 via proteasomal degradation.
Mr Z. Li (CN)
Abstract Slides Video
Presentation thumbnail
Bridging sex differences in HFpEF diagnosis: enhanced predictive performance of the H2FPEF score by incorporating BNP and stepwise E/e′
Doctor J. Weber (Duesseldorf, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Drivers of heart failure with preserved ejection fraction
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 17:30 CET
You may be interested in
thumbnail
Congress Presentation
Systolic blood pressure and outcome in patients admitted with acute heart failure: a pooled analysis from 4 randomized clinical trials.
14 March 2021
thumbnail
Congress Presentation
Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
21 May 2023
thumbnail
Congress Presentation
Association between systolic blood pressure time in target range and incident atrial fibrillation: a prospective cohort study in the UK Biobank
28 August 2026
thumbnail
Congress Presentation
Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources